These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28121742)

  • 1. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
    Santos AH; Casey MJ; Xuerong W; Womer KL
    Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology?
    Santos AH; Chen C; Casey MJ; Womer KL; Wen X
    Nephrol Dial Transplant; 2018 Jan; 33(1):177-184. PubMed ID: 29045704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study.
    Santos AH; Chen C; Alquadan K; Wen X
    Int Urol Nephrol; 2019 Nov; 51(11):2063-2072. PubMed ID: 31385180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus.
    Meier-Kriesche HU; Schold JD; Srinivas TR; Howard RJ; Fujita S; Kaplan B
    Am J Transplant; 2005 Sep; 5(9):2273-80. PubMed ID: 16095509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
    Santos CA; Brennan DC; Yusen RD; Olsen MA
    Transplantation; 2015 Aug; 99(8):1658-66. PubMed ID: 25675196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
    Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
    Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation.
    Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU
    Am J Transplant; 2007 Mar; 7(3):586-94. PubMed ID: 17229066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD; Nezakatgoo N; Lorber MI; Nashan B; Tedesco-Silva H; Kasiske BL; de la Cruz FJ; Russ G; Campistol J; Keown PA;
    Transplantation; 2009 Oct; 88(8):1010-8. PubMed ID: 19855247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-associated smooth muscle tumors after kidney transplantation: treatment and outcomes in a single center.
    Tan CS; Loh HL; Foo MW; Choong LH; Wong KS; Kee TY
    Clin Transplant; 2013; 27(4):E462-8. PubMed ID: 23682851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.